FDA Grants Tentative Approval for 50th and 51st Anti-Retroviral Drugs Under President's AIDS Relief Plan
FDA granted tentative approval for nevirapine tablets, indicated for use with other antiretroviral agents for the treatment of HIV-1 infection, and for the pediatric triple fixed dose combination tablet of lamivudine, stavudine and nevirapine -- the first fixed dose anti-HIV product designed to treat children under the age of 12 years.